Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating polycystic renal disease

A technology for polycystic kidney disease and composition, applied in the field of pharmaceutical compositions and their applications and pharmaceutical preparations containing the same, can solve problems such as unexplained polycystic kidney disease dosage and the like

Active Publication Date: 2007-07-25
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST +1
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The patent does not specify the specific dosage of COX-2 specific inhibitors for the treatment and prevention of polycystic kidney disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating polycystic renal disease
  • Medicine composition for treating polycystic renal disease
  • Medicine composition for treating polycystic renal disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] Example 1 Experimental study on the combined application of a certain concentration of rosiglitazone and celecoxib to inhibit the proliferation of cyst lining epithelial cells

[0079] 1. Experimental method

[0080] 1. Primary cultured human cyst lining epithelial cells, identified by immunohistochemistry and electron microscopy.

[0081] The specimens were obtained from nephrectomy polycystic kidney tissue. Cut the superficial and transparent vesicles, peel off the superficial fibrous membrane, and cut the vesicle wall into debris. After being digested with 0.1% collagenase for 1 hour, the cells were inoculated into culture flasks coated with rat tail collagen, and the culture medium was D-Valine modified MEM containing 20% ​​fetal bovine serum. When cells are close to confluence, digest and passage. Inverted phase-contrast microscope observation. Immunohistochemistry and cell enzyme chemistry were used for cell identification, and electron microscopy was used to ...

Embodiment 2

[0091] Example 2 Comparison of curative effects of combination therapy of rosiglitazone and celecoxib in different concentrations.

[0092] 1. Experimental method

[0093] 1. The BrdU method was used to detect the inhibitory effect of the combination of rosiglitazone and celecoxib in different concentrations on the proliferation of cyst lining epithelial cells.

[0094] The method is the same as above, and the medicines are added according to the following schemes alone or in combination, respectively acting on the cyst lining epithelial cells for 48 hours. Six replicate wells were set up in each group, and the cell proliferation inhibition rate was calculated.

[0095] Single use group: rosiglitazone 25uM (11.84mg / L), rosiglitazone 50uM (23.67mg / L), rosiglitazone 100uM (47.35mg / L); celecoxib 10uM (3.81mg / L ), Celecoxib 20uM (7.62mg / L), Celecoxib 50uM (19.05mg / L).

[0096] Compatibility combination group:

[0097] Rosiglitazone 25uM / celecoxib 10uM (molar ratio 5:2, weight ra...

Embodiment 3

[0107] Example 3 Comparison of curative effects of other thiazolidinediones and COX-2 specific inhibitors in combination with different concentrations.

[0108] According to the method of Example 2, the combination of thiazolidinedione drugs troglitazone and pioglitazone and COX-2 specific inhibitors meloxicam and radicicol alone and in different concentrations were determined. The inhibitory rate of proliferation of cyst lining epithelial cells and the apoptosis rate of cyst lining epithelial cells. The results show that the combination of thiazolidinediones and COX-2 specific inhibitors at different concentrations can also significantly increase the inhibition rate of cyst lining epithelial cell proliferation compared with the two drugs alone, and can significantly promote cyst formation. Apoptosis of lining epithelial cells, with a marked synergistic effect.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composite medicine for treating polycystic kidney disease contains the epoxidase 2(COX-2) specific depressant and the thiazolidbione-type medicine.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for treating polycystic kidney disease, an application thereof and a pharmaceutical preparation containing the same. Background technique [0002] Autosomal dominant polycystic kidney disease (autosomal dominant polycystic kidney disease, ADPKD) is the most common hereditary kidney disease, with a worldwide incidence of about 1 / 400-1 / 1000. Its main pathological feature is the formation of multiple fluid cysts in the cortex and medulla of the bilateral kidneys and progressive growth, which eventually destroys the structure and function of the kidneys, leading to renal failure. ADPKD is also a systemic disease. In addition to involving the kidneys, it can also cause organ lesions such as liver and pancreatic cysts, valvular heart disease, and cerebral aneurysms (Extrarenal manifestations of ADPKD, Perrone RD, Kidney Int.1997; 51(6): 2022 -36). At present, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/426A61P13/12A61K31/415
Inventor 梅长林戴兵顾书华
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com